Key result
Dabigatran use in an 87-year-old man with atrial fibrillation resulted in spontaneous hemopericardium and cardiac tamponade, which was effectively reversed with idarucizumab.
Case Report (n=1)
Highlights a rare bleeding complication of dabigatran (spontaneous hemopericardium and tamponade) and the effectiveness of its reversal agent, idarucizumab.
Alerts clinicians to rare dabigatran tamponade in elderly AF; leaves open incidence and reversal outcomes in broader populations.
Four novel oral anticoagulant agents are currently available for the prevention and treatment of thromboembolic events in patients with nonvalvular atrial fibrillation. We present an unusual case of spontaneous hemopericardium and tamponade in an 87-year-old man with atrial fibrillation who was taking one such agent, dabigatran, as thromboprophylaxis. Our case highlights both a rare bleeding complication of dabigatran use and the effectiveness of idarucizumab, its newly approved reversal agent. Especially in elderly patients, we recommend that clinicians evaluate risk factors, closely monitor patient status, and consider alternatives to the newer anticoagulants when the risk of bleeding is high.
No takes yet. Share an insight, caveat, or question.
Jelani et al. (2017) conducted a case report in Atrial fibrillation (n=1). Dabigatran was evaluated on Spontaneous hemopericardium and tamponade. Dabigatran use in an 87-year-old man with atrial fibrillation resulted in spontaneous hemopericardium and cardiac tamponade, which was effectively reversed with idarucizumab.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: